Advent to acquire a majority stake in Felix Pharmaceuticals for $175m.

Advent, a private equity firm, agreed to acquire a majority stake in Felix Pharmaceuticals, an animal drug producer, for $175m. “As we scale in a fast-evolving market, we were looking for a partner who brings not just capital, but also deep operating expertise and the right mindset and networks to help us grow faster and stronger,” Neeraj Agrawal, Felix Co-Founder.